3 July 2025

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

JAK Safety Update

3 July 2025

ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs

A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (compared with TNFis).

3 July 2025

ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain

The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.

In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with IL

Tweet Author

RheumNow

Tweet Content

In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs. @RheumNow #EULAR2025 #OP0033 https://t.co/nEiTWQEqsP

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden po

Tweet Author

RheumNow

Tweet Content

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/bwXgrB875k

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer

Tweet Author

RheumNow

Tweet Content

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/mdePGkHU82

Who/When to Treat Clinically Suspect Arthralgia

Hidradenitis Suppurativa: What Lies Beneath?

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What m

Tweet Author

RheumNow

Tweet Content

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/Qy9fy3GWKm

Topics

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

JAK Safety Update

In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with IL

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden po

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer

Who/When to Treat Clinically Suspect Arthralgia

Hidradenitis Suppurativa: What Lies Beneath?

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What m

Do you get our email newsletter?